1-[[2-furanyl(oxo)methyl]amino]-3-(3-methylphenyl)thiourea is a **complex organic compound** that can be synthesized in the lab but isn't a widely known or studied molecule with established importance in research.
There's a good chance this specific compound hasn't been extensively researched, and its significance would depend on the context and goals of the research.
However, we can analyze the structure and speculate on potential reasons for its importance:
* **Thiourea Derivatives:** Thioureas are a class of organic compounds with the general formula R₁R₂NC(=S)NR₃R₄. They exhibit a wide range of pharmacological and biological activities, including anti-inflammatory, antimicrobial, anticancer, and antioxidant properties.
* **Furan Ring:** The presence of a furan ring, a five-membered heterocyclic ring with one oxygen atom, is common in naturally occurring compounds and synthetic drugs. Furan derivatives can exhibit various biological activities, including antitumor, antiviral, and antifungal properties.
* **Aromatic Ring:** The 3-methylphenyl group is a benzene ring with a methyl substituent at position 3. Aromatic rings are often found in organic compounds with biological and pharmacological activities, and they contribute to the molecule's structure and interactions with biological targets.
Therefore, the specific combination of thiourea, furan, and aromatic ring functionalities in this compound makes it a potential candidate for studying:
* **Synthesis and characterization of new thiourea derivatives.**
* **Biological activities of thiourea derivatives with a furan ring.**
* **Structure-activity relationships in thiourea-based drug development.**
However, it's crucial to remember that without specific information about the research context, it's impossible to definitively state why 1-[[2-furanyl(oxo)methyl]amino]-3-(3-methylphenyl)thiourea is significant.
**To gain a deeper understanding of its importance, you would need to know:**
* **The specific research area:** What field of research is this compound being studied in (e.g., medicinal chemistry, materials science, etc.)?
* **The research objectives:** What is the goal of the research involving this compound?
* **The experimental results:** What are the findings from the research involving this compound?
Without this context, it's difficult to assess the importance of this specific compound.
ID Source | ID |
---|---|
PubMed CID | 844572 |
CHEMBL ID | 1602060 |
CHEBI ID | 114432 |
Synonym |
---|
smr000200869 |
MLS000582329 |
AK-968/41926334 |
2-(2-furoyl)-n-(3-methylphenyl)hydrazinecarbothioamide |
STK449785 |
2-(furan-2-ylcarbonyl)-n-(3-methylphenyl)hydrazinecarbothioamide |
CHEBI:114432 |
AKOS003260429 |
1-(furan-2-carbonylamino)-3-(3-methylphenyl)thiourea |
HMS2460H24 |
CHEMBL1602060 |
1-[[2-furanyl(oxo)methyl]amino]-3-(3-methylphenyl)thiourea |
Q27195833 |
sr-01000288411 |
SR-01000288411-1 |
Class | Description |
---|---|
furoic acid | A monocarboxylic acid that consists of a furan ring having a single carboxylic acid group on any ring position and derivatives thereof. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 26.8545 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
GLS protein | Homo sapiens (human) | Potency | 12.5893 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 0.6702 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 12.4932 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |